Warning Letter: Similasan

News
Article

ePT--the Electronic Newsletter of Pharmaceutical Technology

Warning Letter: Similasan

On Aug. 16, The US Food and Drug Administration issued a Warning Letter to Similasan AG (Jonen, Switzerland).

The agency’s concerns centered on filling processes and handling of sterilization filters. The letter cited “inadequate” heat-penetration studies of the filter autoclaving process and challenged the company’s practice of re-using filters up to 50 times without bacterial retention tests.

The agency was also concerned about the controls to prevent microbial contamination of sterile eye drops, the lack of written procedures to validate filling processes, and incomplete production and control information in the batch records.

–Douglas McCormick

 

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Drug Digest: Challenges and Triumphs in Next-Generation Biotherapeutic Development
Related Content